Wu Szu-Yuan, Chang Chia-Lun, Chen Chang-I, Huang Chung-Chien
Department of Food Nutrition and Health Biotechnology, Asia University College of Medical and Health Science, Taichung, Taiwan.
Big Data Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan.
JAMA Netw Open. 2021 Aug 2;4(8):e2120156. doi: 10.1001/jamanetworkopen.2021.20156.
Few studies have evaluated long-term surgical complications in patients with prostate cancer (PC) who receive open radical prostatectomy (ORP), laparoscopic radical prostatectomy (LRP), or robot-assisted radical prostatectomy (RARP).
To examine the perioperative and postoperative surgical complications among patients with PC who underwent ORP, LRP, or RARP.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study included patients who received a diagnosis of resectable PC and underwent RP between January 1 and December 31, 2015. Participants were enrolled in the Taiwan Cancer Registry. The index date was the date of surgery, and the follow-up duration was the period from the index date to December 31, 2018. Data analysis was performed in September 2020.
ORP, LRP, or RARP.
Two multivariate mixed models accounting for hospital clusters were fitted to ascertain the association of RARP with treatment outcomes (ie, hospital stay, blood transfusion, postoperative pain, erectile dysfunction, urinary incontinence, and hernia); general linear regression models were used for continuous outcomes, the amount of blood transfused, and hospital stay, and logistic regression models were used for analyzing postoperative outcomes and surgical complications.
Of the 1407 patients included in this study, 315 (22.4%) received ORP (mean [SD] age, 66.4 [6.8] years), 276 (19.6%) received LRP (mean [SD] age, 66.8 [6.4] years), and 816 (58.0%) received RARP (mean [SD] age, 66.1 [6.7] years). Mean (SD) follow-up in the full cohort was 36.7 (4.6) months. No statistically significant differences were observed in age, clinical tumor stage, pathological tumor stage, Gleason score, Gleason grade group, preoperative prostate-specific antigen concentration, D'Amico risk classification, and hospital level. A shorter hospital stay was observed for patients undergoing RARP vs those undergoing ORP (mean [SE] difference, -1.64 [0.22] days; P < .001) and LRP (mean [SE] difference, -0.57 [0.23] days; P = .01). Patients undergoing RARP had lower odds of receiving a blood transfusion (RARP vs ORP: adjusted odds ratio [aOR], 0.25; 95% CI, 0.17-0.36; RARP vs LRP: aOR, 0.58; 95% CI, 0.37-0.91). For postoperative pain, RARP was associated with a decrease in the odds of moderate to severe postoperative pain for as long as 12 weeks compared with both ORP and LRP (eg, RARP vs LRP at week 12: aOR, 0.40; 95% CI, 0.19-0.85; P = .02). The aORs for RARP vs those for ORP and LRP in the third year after RP were, for erectile dysfunction, 0.74 (95% CI, 0.45-0.92) and 0.60 (95% CI, 0.36-0.98), respectively; for urinary incontinence, 0.93 (95% CI, 0.65-0.99) and 0.60 (95% CI, 0.42-0.86), respectively; and for hernia, 0.51 (95% CI, 0.31-0.84) and 0.82 (95% CI, 0.46-0.92), respectively.
In this study, undergoing RARP was associated with fewer acute and chronic postoperative complications than undergoing ORP or LRP.
很少有研究评估接受开放性根治性前列腺切除术(ORP)、腹腔镜根治性前列腺切除术(LRP)或机器人辅助根治性前列腺切除术(RARP)的前列腺癌(PC)患者的长期手术并发症。
研究接受ORP、LRP或RARP的PC患者围手术期和术后的手术并发症。
设计、设置和参与者:这项队列研究纳入了2015年1月1日至12月31日期间被诊断为可切除PC并接受RP的患者。参与者被纳入台湾癌症登记处。索引日期为手术日期,随访期为从索引日期至2018年12月31日。数据分析于2020年9月进行。
ORP、LRP或RARP。
采用两个考虑医院聚类的多变量混合模型来确定RARP与治疗结局(即住院时间、输血、术后疼痛、勃起功能障碍、尿失禁和疝气)之间的关联;一般线性回归模型用于连续结局、输血量和住院时间,逻辑回归模型用于分析术后结局和手术并发症。
本研究纳入的1407例患者中,315例(22.4%)接受ORP(平均[标准差]年龄,66.4[6.8]岁),276例(19.6%)接受LRP(平均[标准差]年龄,66.8[6.4]岁),816例(58.0%)接受RARP(平均[标准差]年龄,66.1[6.7]岁)。整个队列的平均(标准差)随访时间为36.7(4.6)个月。在年龄、临床肿瘤分期、病理肿瘤分期、Gleason评分、Gleason分级组、术前前列腺特异性抗原浓度、D'Amico风险分类和医院级别方面未观察到统计学显著差异。与接受ORP的患者相比,接受RARP的患者住院时间更短(平均[标准误]差异,-1.64[0.22]天;P<0.001),与接受LRP的患者相比也更短(平均[标准误]差异,-0.57[0.23]天;P = 0.01)。接受RARP的患者输血几率较低(RARP与ORP相比:调整后优势比[aOR],0.25;95%置信区间,0.17 - 0.36;RARP与LRP相比:aOR,0.58;95%置信区间,0.37 - 0.91)。对于术后疼痛,与ORP和LRP相比,RARP在长达12周的时间内与中度至重度术后疼痛几率降低相关(例如,第12周时RARP与LRP相比:aOR,0.40;95%置信区间,0.19 - 0.85;P = 0.02)。RP后第三年,RARP与ORP和LRP相比,勃起功能障碍的aOR分别为0.74(95%置信区间,0.45 - 0.92)和0.60(95%置信区间,0.36 - 0.98);尿失禁的aOR分别为0.93(95%置信区间, 0.65 - 0.99)和0.60(95%置信区间, 0.42 - 0.86);疝气的aOR分别为0.51(95%置信区间, 0.31 - 0.84)和0.82(95%置信区间, 0.46 - 0.92)。
在本研究中,与接受ORP或LRP相比,接受RARP的患者术后急慢性并发症更少。